Varda Space Industries manufactures materials in orbit and brings them back to Earth, a business no company had ever run commercially before it. Founded in 2021 by former SpaceX Dragon engineer Will Bruey and Founders Fund partner Delian Asparouhov, it builds the W-Series: free-flying spacecraft that process pharmaceuticals in microgravity and then return the product inside a capsule that reenters at over 18,000 mph and lands under parachute, usually at the Koonibba Test Range in South Australia. The commercial logic is that microgravity produces crystal structures and morphologies that gravity makes impossible on the ground, and Varda proved it on its first flight by growing and recovering the metastable Form III of ritonavir, an HIV antiviral. Six missions have flown since 2023, and five of the six capsules made it home; the fourth, W-4, spent nearly a year on orbit while Varda evaluated a propellant-feed problem before closing out the mission with a disposal burn in May 2026 rather than a recovery. W-5 returned in January 2026 as the first full mission on Varda's own vertically integrated satellite bus, carrying a U.S. Navy payload, and W-6 returned in May 2026 flying thermal-protection and autonomous-navigation experiments for NASA and defense customers under the AFRL's Prometheus program. That second business, selling the capsule as a cheap, high-cadence hypersonic reentry testbed, now runs alongside the pharmaceutical work, and in October 2025 Varda added a third line, agreeing with United Semiconductors to grow semiconductor crystals in microgravity for autonomous-systems, sensing, AI, and defense customers. In May 2026 United Therapeutics signed on to develop microgravity formulations for rare pulmonary disease, the first time a publicly traded pharmaceutical company has spent its own capital on commercial drug manufacturing in space, and Varda leased a former Mattel manufacturing plant in El Segundo in early 2026 to scale spacecraft production to match.
Varda Space Industries announced on August 3 that Mikael Dolsten, who spent 16 years as Chief Scientific Officer and President of Pfizer R&D overseeing more than 36 medicine and vaccine approvals, is joining its board of directors. Varda said Dolsten's experience translating early-stage science into approved medicines will support its push to commercialize space-based pharmaceutical manufacturing, coming three months after publicly traded United Therapeutics became the first pharma company to fund its own microgravity drug-development program on Varda's W-Series capsules.
Free-flying orbital production satellite with an integrated reentry capsule. It processes materials in microgravity independently of any space station, then returns the finished product to Earth under parachute.
Six missions launched since 2023 and five capsules recovered; W-4, the first in-house-built bus, was closed out with a disposal burn on May 10, 2026 after nearly a year evaluating a propellant-feed problem rather than being recovered. The spacecraft bus has been designed and built entirely in-house at El Segundo since W-4, and W-5's January 2026 return was the first complete mission lifecycle flown on Varda hardware end to end.
Missions Flown6 launched, 5 recovered (W-4 disposed of without recovery)
Reentry SpeedOver 18,000 mph, more than Mach 25
RecoveryParachute landing at Koonibba Test Range, South Australia
ManufacturingFull spacecraft built in-house in El Segundo since W-4
The W-Series capsule sold as a flight environment rather than a factory: a repeatable, low-cost way for defense and civil customers to test thermal protection materials, sensors, and guidance systems in real hypersonic reentry conditions.
W-6 launched in March 2026 and returned May 19, 2026 as a dedicated testbed flight funded through the Air Force Research Laboratory's Prometheus program, carrying NASA and defense payloads and validating next-generation thermal protection systems and autonomous navigation. W-5 carried a U.S. Navy payload on its January 2026 return.
ProgramAFRL Prometheus: $48M four-year IDIQ contract, running through early 2028
Testbed Flights in 20262 (W-5 in January, W-6 in May)
Regulatory BasisFAA reentry vehicle operator license, the first ever issued
What's Next
Fly the first United Therapeutics formulation missions
Begin processing small-molecule treatments for rare pulmonary disease aboard W-Series spacecraft under the collaboration announced in May 2026, using microgravity's effect on crystallization to chase formulations with better stability and bioavailability. CEO Will Bruey has said he expects the first United Therapeutics drug to fly in 2027; the partnership covers multiple low Earth orbit missions and is the first time a public pharmaceutical company has funded commercial space manufacturing from its own balance sheet.
2027
Raise reentry cadence toward routine operations
Increase the number of W-Series flights per year now that the spacecraft is built end to end in El Segundo, pursuing the company's stated goal of making reentry as common as launch. Under its expanded reentry agreement with Southern Launch, Varda is aiming to reach near-monthly capsule returns at the Koonibba Test Range by the end of 2028; it flew two recoveries in the first half of 2026 alone, with no seventh mission announced yet as of September 2026.
2028
Track Record
0 of 1 announced date hit · 1 missed
Resolve the W-4 capsule's return
Target 2026 · Resolved May 10, 2026
W-4's reentry attempt, waved off in December 2025 for propellant-feed system evaluation, was never rescheduled. Varda closed out the mission with a disposal burn on May 10, 2026 instead of a capsule recovery, ending W-4's flight without returning its payload. The company said the extra year of data from the standoff informed the W-5 and W-6 missions that followed.
Missed
Operations & Revenue
StatusOperational
Varda has flown six W-Series missions since 2023 and recovered five capsules, two of them in 2026 (W-5 in January and W-6 in May), both at Southern Launch's Koonibba Test Range in South Australia. The sixth vehicle, W-4, never came home: after nearly a year on orbit evaluating a propellant-feed problem, Varda closed out the mission with a disposal burn on May 10, 2026 instead of a recovery. The spacecraft bus is now built entirely in-house at El Segundo, where the company leased a third, 205,400-square-foot building (a former Mattel plant) in early 2026 to scale production, and an office is open in Huntsville near NASA Marshall. The company now runs three revenue lines: microgravity pharmaceutical processing, anchored by the United Therapeutics partnership signed in May 2026; a government hypersonic reentry testbed funded through AFRL's Prometheus program; and, since an October 2025 agreement with United Semiconductors, early-stage semiconductor crystal growth. No new W-Series launch or funding round has been announced since W-6's May 2026 reentry.
Revenue Streams
Pharmaceutical Processing in Microgravity
Contract manufacturing and formulation research for drug companies that want crystal structures and morphologies microgravity makes accessible, sold as processing slots aboard W-Series missions. The United Therapeutics collaboration covers multiple flights for rare pulmonary disease treatments.
Government Hypersonic Reentry Testbed
Selling the capsule itself as a low-cost, high-cadence flight environment for hypersonic and reentry experiments, funded through the Air Force Research Laboratory's Prometheus program and flown for NASA, the U.S. Navy, and defense customers.
Microgravity Research Services
General orbital processing and materials-science capacity for research customers who need a free-flying platform rather than a slot on a crewed space station.
Semiconductor Materials Manufacturing
A multi-flight joint development agreement with United Semiconductors, signed in October 2025, to grow bulk semiconductor and semimetal alloy crystals in microgravity aboard W-Series missions for autonomous-systems, sensing, AI, and defense hardware customers. Still early-stage; no flight-specific revenue has been disclosed.
Key Metrics
Employees
~250
Est. Annual Revenue
Not publicly disclosed (revenue from government reentry testbed contracts including a $48M AFRL Prometheus IDIQ, Navy payloads, pharmaceutical partnerships, and an early-stage semiconductor materials agreement)
Total Funding
$329M raised to date
Missions Launched
6 (W-1 through W-6), 5 capsules recovered (W-4 ended in a disposal burn, not a landing)
Reentry Velocity
Over 18,000 mph (Mach 25+)
Regulatory First
Holder of the FAA's first-ever reentry vehicle operator license (2025)
AFRL Prometheus Contract
$48M four-year IDIQ contract, running through early 2028
Valuation
~$500M (Series C, July 2025)
Timeline
2026W-5 returns on Varda's own vertically integrated bus
Launched November 28, 2025, W-5 lands at Koonibba on January 29, 2026 carrying a U.S. Navy payload. It is the first time Varda has flown a complete mission lifecycle, from orbital operations through reentry, on hardware it designed and built end to end.
2026Leases former Mattel plant in El Segundo to scale production
Varda signs a lease for a 205,400-square-foot former Mattel R&D building about a mile from its headquarters, giving it a third El Segundo site to build production and assembly capacity as it works toward roughly ten more spacecraft built by the end of 2027.
2026W-4 mission ends without recovery
After nearly a year on orbit while Varda evaluated the propellant-feed problem that forced it to wave off the reentry burn in December 2025, the company closes out the W-4 demonstration mission with a disposal burn on May 10, 2026 instead of a capsule recovery. Varda says the extra year of flight data informed the W-5 and W-6 missions that followed.
2026United Therapeutics signs the first commercial pharma partnership
In May 2026 Varda and United Therapeutics announce a collaboration to develop microgravity-enabled formulations of small-molecule treatments for rare pulmonary disease across multiple low Earth orbit missions. It is one of the first times a publicly traded pharmaceutical company has invested its own capital in commercial space-based drug manufacturing rather than relying on government-funded research.
2026W-6 flies as a hypersonic testbed for NASA and defense customers
Launched in March 2026 and recovered at Koonibba on May 19, 2026, W-6 is optimized for atmospheric flight physics rather than pharmaceutical processing. Funded through the Air Force Research Laboratory's Prometheus program, it carries NASA and defense payloads and validates next-generation thermal protection systems and autonomous navigation during hypersonic reentry.
2026Ex-Pfizer R&D chief Mikael Dolsten joins the board
Varda announces on August 3, 2026 that Mikael Dolsten, who spent 16 years as Chief Scientific Officer and President of Pfizer R&D overseeing more than 36 medicine and vaccine approvals, is joining its board of directors - a biopharma-credibility signal three months after United Therapeutics became the first pharma company to fund its own microgravity drug-development program on Varda's W-Series capsules.
2025W-2 and W-3 return to Australia
Varda shifts recovery operations to Southern Launch's Koonibba Test Range in South Australia. W-2 lands in February 2025 and W-3 follows in May 2025, giving the company two Earth returns in roughly two months and establishing a repeatable recovery cadence.
2025W-4 debuts the in-house bus and the FAA's first reentry operator license
W-4 launches in June 2025 on SpaceX's Transporter-14 carrying the first spacecraft bus Varda built itself rather than buying from Rocket Lab, and flies under the first reentry vehicle operator license the FAA has ever issued. Its return was deferred in December 2025 while the company evaluated the propellant feed system, and Varda has described W-4 as a demonstration mission with customer flights taking priority.
2025Varda and United Semiconductors agree to grow semiconductor crystals on orbit
In October 2025 Varda signs a multi-flight joint development agreement with United Semiconductors, which had already grown semiconductor crystals aboard the ISS National Lab, to produce bulk semiconductor and semimetal alloy crystals in microgravity aboard W-Series missions for autonomous-systems, sensing, AI, and defense hardware customers.
2024W-1 capsule returns to Earth
After months of regulatory delay in obtaining reentry approval, the W-1 capsule lands at the Utah Test and Training Range in February 2024 with its ritonavir sample intact. Varda later publishes results showing it recovered the metastable Form III of the drug, a structure difficult to produce on the ground.
2023W-1 launches with the first commercial orbital drug lab
Varda's first spacecraft launches in June 2023 on a Rocket Lab Photon bus and crystallizes ritonavir, an HIV antiviral, in microgravity, the first pharmaceutical ever manufactured commercially in orbit.
2021Founded to manufacture in orbit
Will Bruey, who worked on Dragon at SpaceX, and Delian Asparouhov, a partner at Founders Fund, found Varda in El Segundo with a single premise: microgravity is a manufacturing environment worth paying for, and the missing piece is a cheap way to bring the product home.
Funding
Cumulative disclosed raise · dated rounds
Round
Date
Amount
Investors
Source
Seed
2021
$9M
Lux Capital, Founders Fund, Khosla Ventures
Series A
2021
$42M
Khosla Ventures (lead), Lux Capital, Founders Fund, Caffeinated Capital
Series B
Apr 2024
$90M
Caffeinated Capital (lead), Founders Fund, Khosla Ventures, Lux Capital, Also Capital
Series C
Jul 2025
$187M at a ~$500M valuation
Natural Capital and Shrug Capital (co-leads), Founders Fund, Peter Thiel, Khosla Ventures, Caffeinated Capital, Lux Capital, Also Capital
